125 related articles for article (PubMed ID: 25727020)
1. Omega-3 free fatty acids inhibit tamoxifen-induced cell apoptosis.
Wu S; Guo Y; Wu Y; Zhu S; He Z; Chen YQ
Biochem Biophys Res Commun; 2015 Apr; 459(2):294-299. PubMed ID: 25727020
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 free fatty acids attenuate insulin-promoted breast cancer cell proliferation.
Guo Y; Zhu SL; Wu YK; He Z; Chen YQ
Nutr Res; 2017 Jun; 42():43-50. PubMed ID: 28633870
[TBL] [Abstract][Full Text] [Related]
3. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
4. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
5. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.
Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F
Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054
[TBL] [Abstract][Full Text] [Related]
6. Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention.
Manni A; El-Bayoumy K; Skibinski CG; Thompson HJ; Santucci-Pereira J; Bidinotto LT; Russo J
Biomed Res Int; 2015; 2015():638645. PubMed ID: 26339626
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
[TBL] [Abstract][Full Text] [Related]
8. In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.
Chen JL; Chang CJ; Wang JY; Wen CS; Tseng LM; Chang WC; Noomhorm N; Liu HJ; Chen WS; Chiu JH; Shyr YM
Integr Cancer Ther; 2014 May; 13(3):226-39. PubMed ID: 24525674
[TBL] [Abstract][Full Text] [Related]
9. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
Mandlekar S; Yu R; Tan TH; Kong AN
Cancer Res; 2000 Nov; 60(21):5995-6000. PubMed ID: 11085519
[TBL] [Abstract][Full Text] [Related]
10. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
11. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
[TBL] [Abstract][Full Text] [Related]
12. AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment.
Daurio NA; Tuttle SW; Worth AJ; Song EY; Davis JM; Snyder NW; Blair IA; Koumenis C
Cancer Res; 2016 Jun; 76(11):3295-306. PubMed ID: 27020861
[TBL] [Abstract][Full Text] [Related]
13. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Gee JM; Harper ME; Hutcheson IR; Madden TA; Barrow D; Knowlden JM; McClelland RA; Jordan N; Wakeling AE; Nicholson RI
Endocrinology; 2003 Nov; 144(11):5105-17. PubMed ID: 12960029
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
15. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
17. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells.
Ronghe A; Chatterjee A; Bhat NK; Padhye S; Bhat HK
Oncotarget; 2016 Aug; 7(32):51747-51762. PubMed ID: 27351134
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
20. COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro.
Du Y; Shi A; Han B; Li S; Wu D; Jia H; Zheng C; Ren L; Fan Z
Int J Oncol; 2014 Apr; 44(4):1385-93. PubMed ID: 24535190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
